SurModics, Inc., a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the acquisition of the CodeLink™ Activated Slide microarray business from GE Healthcare.
"Our acquisition of the CodeLink Activated slide business further demonstrates our commitment to building an even stronger In Vitro Technologies business by leveraging SurModics’ core competencies," said Bruce Barclay, president and CEO of SurModics. "Selling these products directly will allow us to get closer to our customers and offer a broader range of products, which is consistent with our strategic growth initiative of diversification. On the heels of our successful acquisition of BioFX Laboratories in August 2007, we continue to enhance the breadth of our In Vitro Technologies product portfolio.”
CodeLink Activated Slides use SurModics’ PhotoLink® technology to create a three-dimensional matrix that allows the attachment of biomolecules (including DNA, RNA and proteins) to form microarrays. SurModics is a pioneer in providing superior surface chemistry to the microarray field, introducing its first genomics product to the market in 1999. SurModics continues to manufacture the products, which since 2000 have been marketed by Motorola, then Amersham, and most recently by GE Healthcare under the CodeLink brand.